High-Precision Base-Editing Therapy Demonstrates Durable VOC-Free Efficacy and Favorable Safety in Sickle Cell Disease
CorrectSequence Therapeutics Reports Positive 15-Month Follow-Up Data for CS-206 SHANGHAI, June 2, 2026 /PRNewswire/ -- CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for severe diseases, announced that the first sickle cell disease (SCD) patient being treated in China with its high-precision base-editing therapy CS-206 has remained free of vaso-occlusive crises (VOCs)...
Phenomenex Launches Endrix Long Life Columns, Redefining Column Durability and Method Reliability
Redefined Column Durability and Method Reliability TORRANCE, Calif., June 1, 2026 /PRNewswire/ -- Phenomenex Inc., a Danaher Company and a global leader in the research and manufacture of advanced technologies for the separation sciences, today introduced the Endrix Long Life LC column, a new liquid chromatography solution engineered for extended column lifetime...
Servier to Acquire Edgewise Therapeutics’ Muscular Dystrophy Business
Acquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs. Transaction includes sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. Transaction represents total value of up to $2.65 billion. SURESNES, France, June 1, 2026 /PRNewswire/ -- Servier, an independent international pharmaceutical group governed...
3billion Launches 3B-NEO, a Genomic Newborn Screening Service Covering 595 Clinically Actionable Genetic Conditions
Screens 595 carefully selected genes associated with childhood-onset conditions where early intervention may improve outcomes Designed for maternity hospitals, obstetrics practices, newborn care providers, pediatric clinics and families seeking earlier genetic insights from birth Expands 3billion's precision medicine platform from rare disease diagnosis into proactive newborn health management SEOUL, South...
Waters Unveils Cyclic IMS P20 MS: The New Benchmark in Structural and Spatial Omics
>10x step-change in MS/MS sensitivity paired with multipass Cyclic™ Ion Mobility Spectrometry (IMS) reveals subtle biological differences for earlier, previously unattainable detection of disease signals. 50% extended upper mass range and comprehensive suite of structural tools advance the development of next-generation biotherapeutics. Integrated MALDI XS and DESI...
Waters Introduces Unrivaled Sensitivity and Speed to Benchtop HRMS with Xevo MRT P10 MS, Accelerating Multiomics Research
Delivers up to 20x improvement in MS/MS sensitivity and 2x faster acquisition speeds, enabling deeper biological insight for next-generation multiomics, therapeutic, and high-throughput workflows. Identifies up to 40% more lipids by LC‑MS/MS than the leading alternative benchtop high‑resolution mass spectrometer, advancing lipidomics research and disease understanding. Sets...
Ranok Therapeutics Announces Positive Interim Phase 1 Data Of Its KRAS G12D Inhibitor RNK08954 In Patients With KRAS G12D-Mutated Metastatic Non-Small Cell Lung Cancer Presented At ASCO 2026
Clinically Meaningful Overall Antitumor Activity, with ORR of 42.9% and DCR of 95.9% across all evaluated dose levels in heavily pretreated patients. Enhanced Clinical Activity at the Recommended Phase 2 Dose (RP2D), with ORR of 50% in patients who were Taxane-Naïve. Differentiated safety profile; RNK08954 was well tolerated, with 1200 mg once daily established as the RP2D. ...
Biond Biologics and Guangzhou-Israel Biotechnology Fund (“GIBF”) Announce Closing of $8 Million Investment and Collaboration
Biond Biologics and Guangzhou-Israel Biotechnology Fund (GIBF) Announce Strategic Investment and Joint Venture to Advance First-in-Class Oncology Programs in China MISGAV, Israel and GUANGZHOU, China, June 1, 2026 /PRNewswire/ -- Biond Biologics Ltd., a private clinical-stage biotechnology company developing first-in-class immunotherapies for cancer and immune-mediated diseases, and the Guangzhou-Israel Biotechnology Fund (GIBF), a leading life science investment fund, today announced...
Ebola disease in Democratic Republic of Congo: MSF scales up response to a rapidly evolving outbreak
HONG KONG, June 1, 2026 /PRNewswire/ -- In eastern Democratic Republic of Congo (DRC), people have been living through insecurity and with an under-resourced health system for years. The Ebola disease outbreak due to the Bundibugyo virus – which does not yet have approved vaccines or specific treatments – is posing a major additional challenge. ...
Haisco Announces Licensing and Research Collaboration Agreement with Lilly to Develop Innovative Medicines Across Multiple Therapeutic Areas
SILICON VALLEY, Calif. and BEIJING, June 1, 2026 /PRNewswire/ -- On May 29, 2026, Haisco Pharmaceutical Group Co., Ltd. ("Haisco") (Ticker Code: 002653) announced a licensing and research collaboration with Eli Lilly and Company ("Lilly") to develop innovative medicines across multiple therapeutic areas. Under the agreement, Haisco will be responsible for the discovery and identification of up to five...
